Abstract
Objective:
The study was aimed to assess the magnitude and associated factors of 2-year seizure-free status of epileptic patients at Mettu Karl Comprehensive Specialized Hospital (MKCSH).
Methods:
A retrospective cross-sectional study was conducted at MKCSH from 12 February 2020 to 11 August 2020. Treatment outcome was measured in terms of seizure control status and seizure frequency. Accordingly, good treatment outcome was declared if the patients had a 2-year seizure-free status and poor if the patient had episodes of seizure in the last 2 years. The pharmaceutical care network Europe guideline was used to assess the presence of medication-related problems. Multivariable logistic regression was used to analyze the variables by using crude odds ratio (COR) and adjusted odds ratio (AOR) with 95% confidence interval (CI). Finally, the predictors of epilepsy treatment outcome were declared if a P-value was ⩽0.05.
Results:
Over the study period, more than half of the participants (172 (57.7%)) were males. The median age of participants was 29 and majorly distributed to 18–30 classes. More than one-fourth of the patients were suffering from absent seizure 85 (28.5%) and general tonic-clonic seizure 83 (27.9%). The most commonly prescribed medication was Phenobarbitone which accounts 34 (11.41%), whereas Valproic acid 8 (2.68%) was the least prescribed. Overall, less than half 131 (43.96%) of patients developed poor treatment outcomes. The predictors of treatment outcomes were having head the injury (AOR = 5.7; 95% CI: 3.18, 10.31), family history of epilepsy (AOR = 5.6; 95% CI: 3.07, 10.46) and the presence of drug therapy problems (AOR = 5.2; 95% CI: 2.79, 9.69).
Conclusion:
The magnitude of poor epilepsy treatment outcome was found to be high. The predictors of epilepsy treatment outcome were the history of head injury, family history of epilepsy and drug therapy problems. Therefore, to improve the treatment outcome of epileptic patients, health care providers should pay close attention to the identified factors. Besides this, the clinical pharmacy service should be implemented to minimize any medication-related problems
Keywords: Associated factors, treatment outcome, epilepsy, MKCSH, Ethiopia
Introduction
Epilepsy is a chronic neurologic disorder characterized by unprovoked frequent seizure attacks which occurred due to excessive discharge of neurons within the central nervous system.1,2 Globally, about 65 million patients had epilepsy, of whom more than three-fourths of them were in lower resource countries like Ethiopia.3–5 It is the second leading cause of neurological disability, morbidity and neurological complications. 6
The mortality rate of epileptic patients was two to three times higher as compared with the general healthy populations. Among a variety of factors associated with poor treatment outcomes of epileptic patients, lack of adequate health care professionals and equipment, non-availability of medications, inadequate drug information, low family income and the presence of comorbidity were the most frequently reported.5,7,8
Although advancements in the pharmacotherapy of epilepsy, seizure was not fully controlled in about one-third of epileptic patients receiving adequate drug therapy.1,8 Despite the majority of antiepileptic drugs (AEDs) could treat the different types of seizure types in epileptic patients, the occurrences of medication-related problems could result in poor treatment outcome for epileptic patients. 4
Nowadays, different adverse drug reactions (ADRs) developed secondary to the use of antiepileptic drugs (AEDs) result in increased hospitalization, change of therapy and unmet goal of therapy. These adverse effects include idiosyncratic reactions, respiratory depression and different neurocognitive effects. 6
Generally, uncontrolled epilepsy treatment outcome might result in decreasing quality of life, disability, neuropsychological pathology, social stigma, impairment of cognition and mortality.1,4
In Ethiopia, the lack of acceptance of patients on modern antiepileptic drugs was highly influenced by their beliefs and cultures as they perceive epilepsy was treated by the traditional healers and spiritual holy water which may push them to not take the medications. 9
Treatment outcome is affected by several factors including drug-related factors, disease-related factors and patient-related factors. Drug-related factors include pharmacokinetics of the drugs, drug–drug interactions and toxicity, among others. Similarly, irrational prescribing concerning drug selection and inappropriate doses will result in poor treatment outcomes. 4 Besides this, various studies revealed that having different treatment protocols, inaccurate epilepsy diagnosis, inappropriate health care providers, lack of modern diagnostic technology, delay in seeking health care and lack of knowledge were the identified factors in the treatment outcome of epilepsy in developing countries. 10 It is estimated that, about 81% of people with epilepsy suffers from perceived epilepsy stigma, which has a direct influence on treatment options. 11
Despite epilepsy being a crucial public health problem, there are scanty studies on the treatment outcomes of epilepsy in Ethiopia in general, and no study conducted in our study area. Therefore, this study was designed to determine the magnitude and predictors of treatment outcomes of epilepsy attending at the ambulatory clinic of MKCSH.
Methods
Study area, design and period
A retrospective cross-sectional study was conducted at Mettu Karl Comprehensive Specialized Hospital (MKCSH) from 12 February 2020 to 11 August 2020. MKCSH is found in Mettu town, South West Oromia, Ethiopia which is found 600 km from Finfinne. The hospital has one chronic care follow-up clinic.
Study participants and eligibility criteria
Adult patients (age ⩾ 18 years) with the diagnosis of epilepsy who have been on regular follow-up for at least 2 years with at least one AED were included in the study. Patients were recruited into the study during their appointment for medication refilling. Patients were excluded if they had a follow-up period of less than 2 years, were seriously ill to complete the interview, refused to give consent, and were those with incomplete medical records.
Study variables and outcome endpoints
Epilepsy treatment outcome was a primary outcome. Treatment outcome was measured in terms of seizure control status and seizure frequency. To evaluate epilepsy treatment outcome, the seizure status of the patients in the last 2-year follow-up period was considered. Accordingly, good treatment outcome was declared if the patients had a 2-year seizure-free status and poor if the patient had episodes of seizure in the last 2 years. 3 The Chalfont seizure severity scale was used to assess the seizure status. 12 Hill-Bone Compliance to Therapy Scale was used to measure the adherence level, 13 and ADR was assessed using the Naranjo et al. 14 algorithm of the ADR probability scale. The pharmaceutical care network Europe guideline was used to assess the presence of medication-related problems.
Sample size and sampling technique
The single population proportion formula was used to calculate the required sample size by considering the proportion of epilepsy treatment outcome P = 0.608, 3 which gives the initial sample size of 366. The final sample size becomes 277 after considering the source population of 1040. Up on addition for 10% contingency, it becomes 298. A simple random sampling was used to include study participants.
Data collection process and management
A semi-structured data collection tool was prepared to collect the data and the relevant information about each patient (demographic data and patients’ clinical characteristics including seizure-related injury) was collected using an interviewer-administered questionnaire.1,3–5,8,13,14 To assure the consistency of the data the 5% of the interviewer-administered questionnaire was pretested at the nearby hospital called Bedele General Hospital before actual data collection. The episodes of seizure-related injury were assessed since the diagnosis of epilepsy. Laboratory results, current medications, comorbidities and relevant previous medical and medication histories were collected using a data abstraction format from a medical chart review. Three medical doctors and two clinical pharmacists were recruited for data collection; one clinical pharmacist was assigned to supervise the data collection process.
Statistical analysis
The data were entered into a computer using EPI-data version 3.1. The principal investigators had daily checked and cleaned the data. The data were then exported to statistical software for social sciences (SPSS) 24.0 for analysis. Multivariable logistic regression was used to analyze the variable by using crude odds ratio (COR) and adjusted odds ratio (AOR) with 95% confidence interval (CI). All variables associated with the epilepsy treatment outcome at a P-value ⩽0.25 on the bivariate analysis were entered into a multivariable logistic regression analysis to control for confounders. Finally, the predictors of epilepsy treatment outcome were declared if a P-value was ⩽0.05.
Ethical approval and consent-to-participate
Ethical approval was obtained from the Research Ethics Review Committee (RERC) of Mettu University with reference no CHS/RERC/89/2020. The study protocol was performed following the Declaration of Helsinki. Permission was given by the administrators and medical directors of MKCSH to conduct the study. The pros and cons of the study were explained to the patients who participated in the study, and written informed consent was obtained from patients. The name of patients and prescribers were not written on the tool to ensure confidentiality.
Operational definitions
Result
Socio-demographic characteristics of participants
Over the study period, more than half of the participants 172 (57.7%) were males. About two-thirds of the male patients 100 (33.56%) have good outcome as compared with female (P = 0.26). The median age of participants was 29 years and majorly distributed to the age of 18–30 years class. The majority 235 (78.9%) of participants were single and of which 135 (45.30%) had a good treatment outcome (P = 0.64). Regarding their educational status, about one-fourth 80 (26.85%) of them who attend a high school had a good treatment outcome (P = 0.29) (Table 1).
Table1.
Socio-demographic characteristics epileptic patients at ambulatory clinic of MKCSH.
| Variables | Category | Treatment outcome | Total | P-value | |
|---|---|---|---|---|---|
| Good | Poor | ||||
| Sex | Male | 100 (33.56%) | 72 (24.16%) | 172 (57.7%) | 0.26 |
| Female | 76 (25.50%) | 50 (16.78%) | 126 (42.3%) | ||
| Age | 18–30 years | 70 (23.49%) | 97 (32.55%) | 167 (56.0%) | 0.34 |
| 30–60 years | 56 (18.79%) | 55 (18.46%) | 111 (37.2%) | 0.52 | |
| >60 years | 12 (4.01%) | 8 (2.68%) | 20 (6.7%) | 0.47 | |
| Resident | Urban | 59 (19.79%) | 66 (22.15%) | 125 (41.9%) | 0.56 |
| Rural | 100 (33.56%) | 73 (24.49%) | 173 (58.1%) | ||
| Marital status | Married | 15 (5.03%) | 16 (5.37%) | 31 (10.4%) | 0.27 |
| Single | 135 (45.30%) | 100 (33.56%) | 235 (78.9%) | 0.64 | |
| Divorced | 7 (2.35%) | 3 (1.0%) | 20 (6.7%) | 0.61 | |
| Widowed | 4 (1.34%) | 8 (2.68%) | 12 (4%) | 0.50 | |
| Level of education | Uneducated | 10 (3.36%) | 12 (4.03%) | 22 (7.4%) | 0.48 |
| Elementary | 45 (15.1%) | 53 (17.79%) | 98 (32.9%) | ||
| High school | 80 (26.85%) | 59 (19.79%) | 139 (46.6%) | ||
| Diploma | 10 (3.36%) | 9 (3.02%) | 19 (6.4%) | ||
| Degree | 5 (1.68%) | 15 (5.03%) | 20 (6.7%) | ||
| Occupation | Farmer/housewife | 43 (14.43%) | 44 (14.77%) | 77 (25.8%) | 0.32 |
| Trader | 19 (6.38%) | 22 (7.38%) | 41 (13.8%) | 0.31 | |
| Government employee | 20 (6.71%) | 10 (3.36%) | 30 (10.1%) | 0.54 | |
| Student | 45 (15.10%) | 55 (18.46%) | 100 (33.6%) | 0.27 | |
| Labor worker | 20 (6.71%) | 20 (6.71%) | 40 (13.4%) | 0.50 | |
| Other | 4 (1.34%) | 6 (2.01%) | 10 (3.4%) | 0.69 | |
| Monthly income (Ethiopian Birr) | Less than 500 | 90 (30.20%) | 33 (11.07%) | 123 (41.3%) | 0.37 |
| 500–1000 | 45 (15.10%) | 30 (10.07%) | 75 (25.2%) | 0.46 | |
| Greater than 1000 | 46 (15.44%) | 54 (18.12%) | 100 (33.6%) | 0.33 | |
Clinical characteristics of the epileptic patients
The treatment outcome was poor in the half of patients 149 (50.0%) who had the onset of seizure of less than 30 years (P = 0.45). The most type of seizure was generalized tonic-clonic (GTC) which accounts 83 (27.9%). Among this, a total of 50 (16.78%) were from patients having a poor outcomes as compared with good outcome accounts 33 (11.07%) (P = 0.26). The treatment outcome was poor in 99 (33.22%) of the patients who had a history of head injury (P = 0.003). About one-fifth 64 (21.48%) of the patients who have a family history of epilepsy had poor treatment outcome (P = 0.01) and 49 (16.44%) of the patients who have a comorbidity had a poor treatment outcome (P = 0.07) (Table 2).
Table 2.
Clinical characteristics of epileptic patients at ambulatory clinic of MKCSH.
| Variables | Category | Treatment outcome | Total | P-value | |
|---|---|---|---|---|---|
| Good | Poor | ||||
| Age at onset | <30 years | 100 (33.55%) | 149 (50.0%) | 249 (83.6%) | 0.45 |
| 30–40 years | 14 (4.7%) | 26 (8.72%) | 40 (13.4%) | 0.52 | |
| ⩾45 years | 2 (0.67%) | 7 (2.35%) | 9 (3%) | 0.28 | |
| Frequency of seizure | <3 | 60 (20.13%) | 100 (33.56%) | 160 (53.7%) | 0.09 |
| >4 | 70 (23.49%) | 68 (22.82%) | 138 (46.3%) | ||
| Duration of epilepsy | <3 years | 110 (36.91%) | 112 (37.58%) | 222 (74.5%) | 0.33 |
| 3–5 years | 4 (1.34 %) | 6 (2.01%) | 10 (3.4%) | 0.41 | |
| >10 years | 25 (8.39 %) | 31 (10.40%) | 66 (22.1%) | 0.48 | |
| Length of hospital stay | ⩽5 years | 34 (11.41 %) | 48 (16.11%) | 82 (27.5%) | 0.31 |
| 6–10 years | 43 (14.43 %) | 43 (14.43%) | 86 (28.9%) | 0.28 | |
| >10 years | 50 (16.78%) | 80 (26.85%) | 130 (43.6%) | 0.64 | |
| History of head injury | Yes | 70 (23.49 %) | 99 (33.22%) | 169 (56.7%) | 0.003 |
| No | 45 (15.10 %) | 84 (28.19%) | 129 (43.3%) | ||
| Type of seizure | General tonic-clonic | 33 (11.07 %) | 50 (16.78%) | 83 (27.9%) | 0.26 |
| Focal | 43 (14.43 %) | 32 (10.74%) | 75 (25.17%) | 0.47 | |
| Absence seizure | 40 (13.42 %) | 45 (15.10%) | 85 (28.5%) | 0.53 | |
| Unclassified | 23 (7.72%) | 32 (10.74%) | 55 (18.46%) | 0.42 | |
| Family history | Yes | 40 (13.42 %) | 64 (21.48%) | 104 (34.9%) | 0.01 |
| No | 96 (32.21%) | 98 (32.89%) | 194 (65.1%) | ||
| Comorbidity | Yes | 43 (14.43%) | 49 (16.44%) | 92 (30.9%) | 0.07 |
| No | 130 (43.62%) | 76 (25.50 %) | 206 (60.1%) | ||
Medication characteristics of epileptic patients
The most commonly prescribed medication was Phenobarbitone which accounts 34 (11.41%). Among them, 20 (6.71%) were prescribed for patients having a good treatment outcome as compared with poor outcome 14 (4.70%)) (P = 0.36). Valproic acid was the least prescribed that accounts 8 (2.68%). Poly-pharmacy was reported among 70 (23.5%) epileptic patients. Drug-related problems were found in 164 (55.0%) participants (Table 3).
Table 3.
Commonly prescribed medications among epileptic patients at ambulatory clinic of MKCSH.
| Drugs given | Treatment outcome | Total | P-value | |
|---|---|---|---|---|
| Good | Poor | |||
| Phenytoin + Insulin | 4 (1.34%) | 5 (1.68%) | 9 (3%) | 0.26 |
| Phenobarbitone + Chlorpromazine | 5 (1.68%) | 5 (1.68%) | 10 (3.4%) | 0.29 |
| Carbamazepine + Phenytoin | 4 (1.34%) | 12 (4.03%) | 12 (4.0%) | 0.51 |
| Phenobarbitone + Amitriptyline | 8 (2.68%) | 12 (4.03%) | 20 (6.7%) | 0.58 |
| Phenobarbitone | 20 (6.71%) | 14 (4.70%) | 34 (11.41%) | 0.36 |
| Phenytoin | 15 (5.03%) | 16 (5.37%) | 31 (10.4%) | 0.62 |
| Phenobarbitone + Valproic acid | 10 (3.36%) | 12 (4.03%) | 22 (7.4%) | 0.50 |
| Phenytoin + Phenobarbitone | 11 (3.69%) | 11 (3.69%) | 21 (7.05%) | 0.49 |
| Phenobarbitone + Nifedipine | 13 (4.36%) | 19 (6.38%) | 32 (10.74%) | 0.52 |
| Valproic acid | 3 (1.0%) | 5 (1.68%) | 8 (2.68%) | 0.58 |
| Aspirin + Phenobarbitone | 4 (1.34%) | 6 (2.01%) | 10 (3.4%) | 0.28 |
| Loratadine + Valproic acid + Chlorpromazine | 10 (3.36%) | 12 (4.03%) | 22 (7.4%) | 0.32 |
| Phenobarbitone + Carbamazepine | 8 (2.68%) | 4 (1.34%) | 12 (4.02%) | 0.31 |
| Phenytoin + Valproic acid | 10 (3.36%) | 14 (5.0%) | 24 (8.36%) | 0.55 |
| Phenobarbitone + Amitriptyline | 14 (5.0%) | 17 (5.70%) | 31 (10.7%) | 0.41 |
Prevalence and types of DRPs
The prevalence of actual or potential DTPs among subjects put on at least a single drug was found to be 164 (55.0%). A total of 323 DRPs were identified on average, 1.084 DRPs per patient. The three leading categories of drug-related problems found to be a culprit among the sample were needs additional drug therapy 72 (22.29%), dose too low 52 (16.09%) and dose to high 50 (15.48%) (Table 4).
Table 4.
Types of drug therapy problems of the patients admitted to medical ward of MKCSH.
| Types of drug therapy problems | Frequency (n) | Percentage (%) |
|---|---|---|
| Ineffective drug therapy | 42 | 13.00% |
| Non-adherence | 48 | 14.86% |
| Dose too high | 50 | 15.48% |
| Needs additional drug therapy | 72 | 22.29% |
| Dose too low | 52 | 16.09% |
| Unnecessary drug therapy | 49 | 15.17% |
| ADR | 10 | 3.09% |
ADR: adverse drug reaction.
The treatment outcome of patients
Among epileptic patients, the treatment outcome was good in 167 (56.04%) of the patients, and less than half (131 (43.96%)) of patients developed poor treatment outcomes in which their seizure was not controlled despite antiepileptic drugs.
Factors associated with treatment outcome of epileptic patients
The results of the bivariate analysis revealed that frequency of seizure, history of head injury, comorbidity, drug therapy problem and family history of epilepsy were shown associated with treatment outcome. In the multivariate analysis, variables including the history of head injury, drug therapy problem and family history of epilepsy kept their association after controlling confounders. Patients who had head injury were 5.7 times more likely to have poor treatment outcomes when compared with patients who had no history of head injury (AOR = 5.7; 95% CI: 3.18, 10.31). The probability of poor treatment outcome was 5.6 times higher among patients who have a family history of epilepsy than their counterparts (AOR = 5.6; 95% CI: 3.07, 10.46). Moreover, patients who had drug therapy problems were 5.2 times more likely to develop poor treatment outcome compared with patients who had no therapy problems (AOR = 5.2; 95% CI: 2.79, 9.69) (Table 5).
Table 5.
Multivariable logistic regression analysis results of factors associated with epilepsy treatment outcome among epileptic patients at chronic care follow-up of MKCSH.
| Variables | Categories | Treatment outcome | COR (95 % CI) | AOR (95 % CI) | P-value | |
|---|---|---|---|---|---|---|
| Good | Poor | |||||
| Frequency of seizure | <3 | 100 (33.56%) | 60 (20.13%) | 1 | 1 | 0.086 |
| >4 | 67 (22.48%) | 71 (23.83%) | 1.77 (0.91, 2.2.81) | 1.40 (0.89, 4.01) | ||
| History of head injury | Yes | 67 (22.48%) | 102 (34.23%) | 5.3 (3.14, 8.79) | 5.7 (3.18, 10.31) | 0.012 |
| Comorbidity | Yes | 33 (11.07%) | 59 (19.80%) | 3.3 (1.99, 5.56) | 2.66 (0.78, 6.09) | 0.157 |
| Drug therapy problem | Yes | 75 (25.17%) | 89 (29.87%) | 2.6 (1.61, 4.19) | 5.2 (2.79, 9.69) | < 0.001 |
| Family history | Yes | 35 (11.74%) | 69 (23.15%) | 4.2 (2.53, 6.96) | 5.6 (3.07, 10.46) | 0.04 |
AOR: adjusted odds ratio; CI: confidence interval; COR: crudes odds ratio.
Discussion
This institution-based retrospective study assessed epilepsy treatment outcomes and its associated factors among ambulatory patients. Accordingly, 44% of patients developed poor treatment outcomes (37.9%–49.7% CI). This finding is lower than a findings from the United Kingdom, Aydel Hospital and Mizan-Tepi University Teaching Hospital where 57%, 53.4% and 60.8% of patients had poor treatment outcomes, respectively.1,3,15 This dissimilarity may be related to the gap in the study period and the difference in study design. The recent finding is congruent with the previous studies conducted in Qatar, the Amhara region, Ambo Hospital and Jimma University Specialized Hospital (JUSH) where 46%, 44 %, 44.7% and 43.3% of patients had poor treatment outcomes, respectively.5,8,16,17 The recent finding is higher than the cross-sectional studies conducted in the United States and Scotland where 8% and 36.3% of patients had poorly controlled seizures.18,19 Similarly, it is higher than a study conducted in Tikur Anbessa Specialized Hospital (TASH) in which 34.4% of patients developed uncontrolled seizures. 4 The possible reason for this discrepancy could be due to differences in study design and socio-demographic variation in the two populations.
Evidence has shown an association between head injury and treatment outcome11,19; likewise, in our study patients who had a history of head injury were 5.7 times more likely to develop poor treatment outcomes when compared with their counterparts. Also, this association is consistent with a study conducted at Mizan-Tepi University Teaching Hospital. 3
In this study, the odds of poor treatment outcome was 5.6 times higher among patients who had a family history of epilepsy compared with their counterparts. This finding is consistent with a findings from Scotland and Qatar.17,19
Epileptic patients who have drug therapy problems was 5.2 times more likely to develop poor treatment outcomes as compared with those who had no drug therapy problems. This finding was not supported by the literature. The possible reason for this association may be the fact any problem in therapy come up with poor treatment outcome and non-adherence.
In our study, the most type of seizure was generalized tonic-clonic (GTC) which accounts 83 (27.9%). Among this, a total of 50 (16.78%) were from patients having poor outcomes as compared with good outcome accounts 33 (11.07 %). This was consistent with the study of Saudi Arabia 20 and Mizan-Tepi University Teaching Hospital, Southwest Ethiopia. 3 The reason for this might be patients having a generalized tonic-clonic (GTC) seizure may present with violent body movements and often prominent autonomic changes. As a result, the health care seeking in those populations is higher than other types of seizures.
Phenobarbitone was the most commonly administered AED 34 (11.41%). Among them, 20 (6.71%) were prescribed for patients having a good treatment outcome as compared with poor outcome 14 (4.70%). This is consistent with the study of the University of Gondar Teaching Hospital. 21 On the contrary, Valproic acid was commonly prescribed in Saudi Arabia. 19 This might be due to the physicians’ preferences and availability of the drugs. As limitation, the study was a single center and a retrospective study and the causal effect relationship were not determined.
Conclusion
The magnitude of poor epilepsy treatment outcome was found to be high. Factors like the history of head injury, family history of epilepsy, and drug therapy problems were shown significant association with treatment outcome. Therefore, to improve the treatment outcome of epileptic patients, health care providers, as well as local, regional and national governments, should pay close attention to the identified factors. Besides this, the clinical pharmacy service should be implemented to minimize any medication-related problems.
Research Data
This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
sj-docx-1-smo-10.1177_20503121221125149 for Treatment outcome and associated factors among epileptic patients at ambulatory clinic of Mettu Karl Comprehensive Specialized Hospital: A cross-sectional study by Firomsa Bekele and Wubishet Gezimu in SAGE Open Medicine
Supplemental material, sj-docx-2-smo-10.1177_20503121221125149 for Treatment outcome and associated factors among epileptic patients at ambulatory clinic of Mettu Karl Comprehensive Specialized Hospital: A cross-sectional study by Firomsa Bekele and Wubishet Gezimu in SAGE Open Medicine
Acknowledgments
We thank Mattu University for providing the chance to conduct this study. We also acknowledge the hospital administrators and data collectors for extending their helping hands toward our study.
Footnotes
Author contributions: FB contributes to the preparation of research, methodology, and statistical analysis. WG participated in preparing the first draft of the article. FB and WG contributed to the editing of the article. Both authors checked and confirmed the final version of the article.
Availability of data and materials: The materials used while conducting this study are obtained from the corresponding author on reasonable request.
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Ethical approval: Ethical approval was obtained from the Research Ethics Review Committee (RERC) of the Mattu University with no CHS/RERC/89/2020.
Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.
Informed consent: The pros and cons of the study were explained to the patients participated in the study, and written informed consent was obtained from patients. The name of patients and prescribers were not written on the tool to ensure confidentiality.
ORCID iDs: Firomsa Bekele 
https://orcid.org/0000-0002-7855-9838
Wubishet Gezimu
https://orcid.org/0000-0002-5503-1360
Supplemental material: Supplemental material for this article is available online.
References
- 1. Niriayo YL, Mamo A, Kassa TD, et al. Treatment outcome and associated factors among patients with epilepsy. Sci Rep 2018; 8: 17354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. World Health Organization. Epilepsy in the WHO African region: bridging the gap: the global campaign against epilepsy “out of the shadows,” 2004, https://www.ecoi.net/en/file/local/1320358/432_1198069054_epilepsy-in-african-region.pdf
- 3. Zewudie A, Mamo Y, Feyissa D, et al. Epilepsy treatment outcome and its predictors among ambulatory patients with epilepsy at Mizan-Tepi University Teaching Hospital, Southwest Ethiopia. Neurol Res Int 2020; 2020: 8109858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Nasir BB, Yifru YM, Engidawork E, et al. Antiepileptic drug treatment outcomes and seizure-related injuries among adult patients with epilepsy in a tertiary care hospital in Ethiopia. Patient Relat Outcome Meas 2020; 11: 119–127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Mekonentefera G, Woldehaimanot TE, Tarekegn M. Poor treatment outcomes and associated factors among epileptic patients at Ambo Hospital, Ethiopia. Gaziantep Med J 2015; 21(1): 9–16. [Google Scholar]
- 6. Ayalew MB, Muche EA. Patient reported adverse events among epileptic patients taking antiepileptic drugs. SAGE Open Med 2018; 6: 1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Ahmed I, Tesema AA, Demeke T. Medication adherence and associated factors among patients with epilepsy at follow up clinics of Jimma town public hospitals, Jimma, South West, Ethiopia, 2019. J Pharmacol Clin Res 2020; 8(1): 555735. [Google Scholar]
- 8. Biset G, Woday A. Epilepsy treatment outcomes in referral hospitals of northeast Ethiopia. Epilepsy Res 2021; 171: 106584. [DOI] [PubMed] [Google Scholar]
- 9. Belayneh Z, Mekuriaw B. A systematic review and meta-analysis of anti-epileptic medication non-adherence among people with epilepsy in Ethiopia. Arch Public Health 2020; 78: 23–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Beyene A, Ayalew AF, Mulat G, et al. The treatment outcomes of epilepsy and its root causes in children attending at the University of Gondar teaching hospital: a retrospective cohort study, 2018. PLoS ONE 2020; 15(3): e0230187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Molla A, Mekuriaw B, Habtamu E, et al. Treatment-seeking behavior towards epilepsy among rural residents in Ethiopia: a cross-sectional study. Neuropsychiatr Dis Treat 2020; 16: 433–439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Duncan JS, Sander JWAS. The Chalfont seizure severity scale. J Neurol Neurosurg Psychiatry 1991; 54: 873–876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Song Y, Han HR, Song HJ, et al. Psychometric evaluation of hill-bone medication adherence subscale. Asian Nurs Res 2011; 5(3): 183–188. [DOI] [PubMed] [Google Scholar]
- 14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–245. [DOI] [PubMed] [Google Scholar]
- 15. Jones RM, Butler JA, Thomas VA, et al. Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure 2006; 15(7): 504–508. [DOI] [PubMed] [Google Scholar]
- 16. Gurshaw M, Agalu A, Chanie T. Anti-epileptic drug utilization and treatment outcome among epileptic patients on follow-up in a resource poor setting. J Young Pharm 2014; 6(3): 47–52. [Google Scholar]
- 17. Haddad N, Melikyan G, Al Hail H, et al. Epilepsy in Qatar: causes, treatment, and outcome. Epilepsy Behav 2016; 63: 98–102. [DOI] [PubMed] [Google Scholar]
- 18. Hovinga CA, Asato MR, Manjunath R, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 2008; 13: 316–322. [DOI] [PubMed] [Google Scholar]
- 19. Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. JAMA Neurol 2018; 75(3): 279–286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Gabr WM, Shams ME. Adherence to medication among outpatient adolescents with epilepsy. Saudi Pharm J 2015; 23(1): 33–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Birru EM, Shafi M, Geta M. Drug therapy of epileptic seizures among adult epileptic outpatients of University of Gondar Referral and Teaching Hospital, Gondar, North West Ethiopia. Neuropsychiatr Dis Treat 2016; 12: 3213–3219. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
sj-docx-1-smo-10.1177_20503121221125149 for Treatment outcome and associated factors among epileptic patients at ambulatory clinic of Mettu Karl Comprehensive Specialized Hospital: A cross-sectional study by Firomsa Bekele and Wubishet Gezimu in SAGE Open Medicine
Supplemental material, sj-docx-2-smo-10.1177_20503121221125149 for Treatment outcome and associated factors among epileptic patients at ambulatory clinic of Mettu Karl Comprehensive Specialized Hospital: A cross-sectional study by Firomsa Bekele and Wubishet Gezimu in SAGE Open Medicine